From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma The treatment landscape for unresectable hepatocellular carcinoma has undergone profound change over the past 5 years, presenting both unprecedented opportunities and complex decision-making challenge...

Please have a look at our editorial published in #ASCODailyNews
@ascocancer.bsky.social @antoniodalessio.bsky.social @cirocelsa.bsky.social
From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma dailynews.ascopubs.org/do/sorafenib...

@salvatorepetta @graziapennisi @albertomantovani @giovannitargher

Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising effects on liver histology in phase 2 trials enrolling patients with metabolic dysfunction-associated steatotic liv...

📣Now online our new study on #GLP1RA and liver outcomes!🔬
GLP-1 agonists reduce risk of major liver events in T2 diabetes pts.
Meta-analysis of 1.4+ million pts shows ⬇️ risk of decompensation and potential reduction in HCC @giuseppecabibbo.bsky.social @djpinato.bsky.social
doi.org/10.1136/gutj...

@vincenzacalvaruso @marcocarbone

In press on @amergastroassn.bsky.social journal CGH
our multicenter study on 293 pts with PBC from Italy/UK
🔥 Non-invasive tests for portal hypertension perform poorly when cholestasis is severe.
👊RESIST criteria (PLT+albumin) outperform stiffness-based criteria
www.cghjournal.org/article/S154...

Looking forward to collaborate again !

Thrilled to have participated in EASL-AASLD Masterclass in beautiful #Savannah. Amazing opportunity to exchange insights, networking and advance expertise in #liver diseases with global leaders. Grateful for this enriching experience! #Liversky

OUR TEAM WON

Proud mama over here